Table 1. Patient characteristics.
| Patient characteristics | CDI positive (n = 144) | CDI negative (n = 144) |
|---|---|---|
| Median age (range) | 67 (21–90) | 67 (21–89) |
| Sex | ||
| Male | 69 (48%) | 69 (48%) |
| Female | 75 (52%) | 75 (52%) |
| Received antimicrobials 4 weeks before diarrhea | ||
| Yes | 93 (78.8%) | 80 (67.2%) |
| No | 25 (21.2%) | 39 (32.8%) |
| Unknown | 26 | 25 |
| Antimicrobial classes | ||
| Penicillin/Cephalosporins | 63 (53.4%) | 50 (42%) |
| Glycopeptides | 17 (14.4%) | 14 (11.8%) |
| Carbapenems | 19 (16.1%) | 15 (12.6%) |
| Quinolones | 47 (39.8%) | 43 (36.1%%) |
| Clindamycin | 4 (3.4%) | 2 (1.7%) |
| Metronidazole | 15 (12.8%) | 6 (5%) |
| Folic acid antagonists | 11 (9.3%) | 2 (1.7%) |
| Other | 33 (28%) | 16 (13.4%) |
| Reason for hospitalization | ||
| Elective chemotherapy | 50 (39.0%) | 79 (56.0%) |
| Diarrhea | 18 (14.1%) | 13 (9.2%) |
| Other (Mainly worsening general condition and dyspnea) | 60 (46.9%) | 49 (34.8%) |
| Unknown | 16 | 3 |
| Chemotherapy within 30 days before diarrhea | ||
| Yes | 61 (43.9%) | 95 (68.3%) |
| No | 78 (56.1%) | 44 (31.7%) |
| Unknown Type | 5 | 5 |
| Platinum drugs | 14 (10.1%) | 24 (17.3%) |
| Anthracyclines | 17 (12.2%) | 31 (22.3%) |
| 5-FU and derivatives | 10 (7.2%) | 14 (10.1%) |
| Other antimetabolites | 28 (20.1%) | 45 (32.4%) |
| Taxanes | 8 (5.8%) | 16 (11.5%) |
| Vinca alkaloids | 11 (7.9%) | 16 (11.5%) |
| Topoisomerase inhibitors | 16 (11.5%) | 25 (18.0%) |
| Other Alkylating agents | 9 (6.5%) | 14 (10.1%) |
| Targeted therapies | 26 (18.7%) | 25 (18.0%) |
| Underlying disease | ||
| Hematologic disease | 73 (50.7%) | 69 (47.9%) |
| Solid tumor | 68 (47.2%) | 75 (52.1%) |
| Both | 3 (2.1%) | 0 (0%) |
| AML | 22 (15.3%) | 29 (20.3%) |
| AML plus solid tumor | 3 (2.1%) | 0 (0%) |
| ALL | 5 (3.4%) | 7 (4.9%) |
| Astrocytoma | 0 (0%) | 1 (0.7%) |
| Bladder cancer | 3 (2.1%) | 3 (2.1%) |
| Breast cancer | 12 (8.3%) | 9 (6.3%) |
| Cholangiocellular carcinoma | 1 (0.7%) | 1 (0.7%) |
| Cervix carcinoma and endometrial cancer | 3 (2.1%) | 1 (0.7%) |
| CLL | 7 (4.9%) | 1 (0.7%) |
| CML | 0 (0%) | 1 (0.7%) |
| CMML | 4 (2.8%) | 0 (0%) |
| Colorectal cancer | 6 (4.2%) | 11 (7.7%) |
| CUP | 0 (0%) | 5 (3.5%) |
| Head and neck cancer | 1 (0.7%) | 2 (1.4%) |
| Lung cancer | 12 (8.3%) | 6 (4.2%) |
| Lymphoma | 27 (18.8%) | 21 (14.7%) |
| MDS | 2 (1.4%) | 3 (2.1%) |
| Mesothelioma | 2 (1.4%) | 0 (0%) |
| Myeloma | 5 (3.5%) | 7 (4.9%) |
| NET lung, bladder and pancreatic | 0 (0%) | 5 (3.5%) |
| Esophagial and gastric cancer | 7 (4.9%) | 10 (7.0%) |
| Ovarian cancer | 1 (0.7%) | 2 (1.4%) |
| Pancreatic cancer | 10 (6.9%) | 4 (2.8%) |
| Prostate cancer | 3 (2.1%) | 6 (4.2%) |
| Peritoneal carcinoma | 1 (0.7%) | 0 (0%) |
| Renal cell carcinoma | 4 (2.8%) | 3 (2.1%) |
| Sarcoma | 3 (2.1%) | 4 (2.8%) |
| Seminoma | 0 (0%) | 1 (0.7%) |
| Unknown | 0 | 1 |
Percentages refer to non-missing values; acute myeloid leukemia (AML); acute lymphocytic leukemia (ALL); chronic lymphoid leukemia (CLL); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); cancer of unknown primary (CUP); myelodysplatic syndrome (MDS); neuroendocrine tumor (NET).